Taming Glioblastoma by Targeting Angiogenesis: 3 Years Later

[1] [Anonymous], FDA APPR BEV

[2] Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4714 - 4721

[3] A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer [J]. SEMINARS IN ONCOLOGY, 2003, 30 (05) : 117 - 124

[4] De Groot John F., 2010, Proceedings of the American Association for Cancer Research Annual Meeting, V51, P553

[5] DVORAK HF, 1986, NEW ENGL J MED, V315, P1650

[6] Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4733 - 4740

[7] Enzastaurin in the Treatment of Recurrent Glioblastoma: A Promise That Did Not Materialize [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1097 - 1098

[8] Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1830 - 1835

[9] Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2184 - 2191

[10] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 60 - 65

[1] [Anonymous], FDA APPR BEV

[2] Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4714 - 4721

[3] A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer [J]. SEMINARS IN ONCOLOGY, 2003, 30 (05) : 117 - 124

[4] De Groot John F., 2010, Proceedings of the American Association for Cancer Research Annual Meeting, V51, P553

[5] DVORAK HF, 1986, NEW ENGL J MED, V315, P1650

[6] Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4733 - 4740

[7] Enzastaurin in the Treatment of Recurrent Glioblastoma: A Promise That Did Not Materialize [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1097 - 1098

[8] Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1830 - 1835

[9] Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2184 - 2191

[10] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 60 - 65